Virtual Roundtable to Explore Neuropsychiatric Treatment Innovations
In an effort to address the pressing issues faced by individuals dealing with neuropsychiatric conditions, a unique virtual roundtable is set to occur. This event emphasizes the advancements in treating acute agitation, particularly for those grappling with bipolar disorder and schizophrenia. It is hosted by Anjalee Khemlani, a renowned journalist known for her insightful coverage in the healthcare sector.
Event Overview and Contributors
The virtual event will commence at 10 a.m. EST. This hour-long discussion features a roster of distinguished medical professionals presenting invaluable insights into modern approaches for managing episodes of agitation. The discussions will also cover the practical advantages of self-administered treatments that can be utilized at home.
Expert Participants
Among the experts leading this discussion are:
- Leslie Citrome, M.D., M.P.H., Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College.
- Marc A. Milano, M.D., FACEP, Chair of the Department of Emergency Medicine at Newark Beth Israel Medical Center.
- Leon Ravin, M.D., a psychiatrist with a focus on public and behavioral health in Nevada.
Significance of Addressing Agitation
With millions of episodes of agitation linked to bipolar disorder and schizophrenia occurring annually, this roundtable is pivotal. It offers caregivers, clinicians, and healthcare professionals a platform to understand the evolving treatment paradigms that are moving beyond traditional settings like emergency rooms and psychiatric facilities.
Encouraging Home-Based Treatment Approaches
The emphasis on self-administered treatments is particularly noteworthy. These innovations not only seek to empower patients but may also help reduce the burden on healthcare systems. By discussing new therapeutic options, participants will explore how these treatments can facilitate a more manageable and comfortable home environment for patients.
Interactive Q&A Session
During the event, attendees will have the opportunity to engage with panelists through a written Q&A session, allowing for a deeper understanding of the topics discussed. Questions pertaining to practical applications or personal experiences with treatment options will be encouraged.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is at the forefront of developing groundbreaking medicines, particularly in the field of neuroscience. Leveraging artificial intelligence, the company seeks to transform patient care and improve the quality of life for individuals living with challenging medical conditions. Its advancements in drug re-innovation aim to repurpose existing medications, thereby unlocking new therapeutic possibilities.
Company Contact Information
For further inquiries regarding the event or BioXcel Therapeutics, interested parties can reach out to:
Corporate/Investors:
Nic Johnson, Russo Partners
Email: nic.johnson@russopartnersllc.com
Phone: 1.303.482.6405
Additional Media Contacts
For media-related inquiries, contact:
David Schull, Russo Partners
Email: david.schull@russopartnersllc.com
Phone: 1.858.717.2310
Frequently Asked Questions
What is the focus of the upcoming virtual roundtable?
The virtual roundtable will discuss the latest advancements in treating acute agitation related to neuropsychiatric conditions.
Who is hosting the virtual roundtable?
Anjalee Khemlani, an award-winning health journalist, is hosting the event.
What time does the event take place?
The event is scheduled for 10 a.m. EST.
How can participants engage during the event?
Participants can submit questions via a written Q&A session during the event.
What is BioXcel Therapeutics, Inc. known for?
BioXcel Therapeutics is recognized for developing innovative medicines in neuroscience by leveraging artificial intelligence and existing drug therapies.
